Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/10/2020
SIETES contiene 93129 citas

 
 
<< anterior 21 a 40 de 8088 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Hermida RC, Crespo JJ, Domínguez-Sardina M, et al.. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2019:septiembre. [Ref.ID 103201]
22.Enlace a cita original Cita con resumen
Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen RJ, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394:24 de octubre. [Ref.ID 103199]
23.Enlace a cita original Cita con resumen
Schäfer W, Princk C, Kollhorst B, Schink T. Antidepressants and the risk of hemorrhagic stroke in the elderly: a nested case–control study. Drug Saf 2019;42:septiembre. [Ref.ID 103178]
24. Cita con resumen
Thayakaran R, Adderley NJ, Sainsbury C, Torlinska B, Sumilo D, Thomas GN, Toulis KA, Nirantharakumar K. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. BMJ 2019;366:3 de septiembre. [Ref.ID 103172]
25.Enlace a cita original Cita con resumen
Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia. A nested case-control study. JAMA Intern Med 2019;179:agosto. [Ref.ID 103160]
26.Enlace a cita original Cita con resumen
Perkovic V, Jardine MJ, Neal BBompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, for the CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:13 de junio. [Ref.ID 103155]
27.Enlace a cita original Cita con resumen
Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie MA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG, US Multiple Sclerosis Prevalence Workgroup. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology 2019;92:5 de marzo. [Ref.ID 103132]
28.Enlace a cita original Cita con resumen
Ma H, Li X, Sun D, Zhou T, Ley SH, Gustat J, Heianza Y, Qi L. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ 2019;365:l1628. [Ref.ID 103121]
29.Enlace a cita original Cita con resumen
Garmendia CA, Gorra LN, Rodríguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses. The example of the apixaban trials. JAMA Intern Med 2019;179:4 de marzo. [Ref.ID 103094]
30.Enlace a cita original Cita con resumen
Liu B, Luo Z, Pinto JM, Shiroma EJ, Tranah GJ, Wirdefeldt K, Fang F, Harris TB, Chen H. Relationship between poor olfaction and mortality among community-dwelling older adults: a cohort study. Ann Intern Med 2019:30 de abril. [Ref.ID 103093]
31. Cita con resumen
Akyea RK, Kai J, Qureshi N, Iyen B, Weng SF. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart 2019:15 de abril. [Ref.ID 103087]
32.Enlace a cita original Cita con resumen
Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ 2019;365:4 de abril. [Ref.ID 103086]
33.Enlace a cita original Cita con resumen
Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]
34.Enlace a cita original Cita con resumen
Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med 2019;179:mayo. [Ref.ID 103073]
36. Cita con resumen
Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]
37.Enlace a cita original Cita con resumen
Hurley R. Medical cannabis: no NHS patients have benefited from law change, say campaigners. BMJ 2019;364:15 de febrero. [Ref.ID 103033]
38. Cita con resumen
Jones G. GW Pharma's cannabis-based medicine to be tested in dementia. PMLiVE 2019:1. [Ref.ID 103025]
39.Enlace a cita original Cita con resumen
Josephson CB, Engbers JDT, Jette N, Patten SB, Sinqh S, Sajobi TT, Marshall D, Agha-Khani Y, Federico P, Mackie A, Macrodimitris S, McLane B, Pillay N, Sharma R, Wiebe S. Prediction tools for psychiatric adverse effects after levetiracetam prescription. JAMA Neurology 2019:enero. [Ref.ID 103020]
40.Enlace a cita original Cita con resumen
Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:2 de febrero. [Ref.ID 103016]
Seleccionar todas
 
<< anterior 21 a 40 de 8088 siguiente >>